Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Operating expenses:    
Research and development expenses $ 2,328,087 $ 770,427
General and administrative expenses 4,859,369 6,479,193
Impairment of intangible assets 461,715 718,970
Total operating expenses 7,649,171 7,968,590
Operating loss (7,649,171) (7,968,590)
Change in fair value of common stock warrants (280,747)  
Warrant financing expense (192,817)  
Other income, net 154 1,599,705
Loss before income taxes (8,122,581) (6,368,885)
Net loss (8,122,581) (6,368,885)
Deemed dividend attributable to Series A preferred stock (2,568,132)  
Net loss attributable to common stockholders $ (10,690,713) $ (6,368,885)
Loss per common share - basic and diluted (in dollars per share) $ (0.91) $ (2.16)
Weighted average shares outstanding, basic and diluted (in shares) 11,697,273 2,947,282